Cellbricks
Developing implantable vascularized human tissue grafts via proprietary high-resolution light-based 3D bioprinting.
- CEO / Founder
- Alexander Leutner and Simon MacKenzie (Co-CEOs)
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- €10M
- Key Investors
- Silicon Roundabout Ventures (lead); SPRIND; ACT Venture Partners; B.value
Technology & Products
Key Products
Biofabricated tissue implants for soft tissue repair, wound healing, and trauma care.
Technological Advantage
Proprietary DLP-based bioprinting process; interdisciplinary expertise in tissue engineering; validated through zero-gravity R&D and animal trials.
Differentiation
Value Proposition
Enables the production of vascularized human tissues and organ models with high resolution, reducing the gap between lab-grown tissues and clinical implants.
How They Differentiate
Focus on high-resolution vascularization and scalable tissue therapeutics using tailor-made biomaterials.
Market & Competition
Target Customers
Regenerative medicine patients and researchers
Industry Verticals
Medical; Biotechnology; Regenerative Medicine
Competitors
Allevi, Regemat 3D, Cellink
Growth & Milestones
Growth Metrics
€10M raise in March 2026; Positive animal trials in April 2025; Team of 20-30 from 14 nations
Major Milestones
Founded in 2017; Earliest operations as Cellbricks GmbH in 2018; Received Bayer G4A and BMBF grants; Closed EUR 5M Seed II round; Established Boston expansion hub; Initiated in vivo studies for liver patches and breast implants; Zero-gravity bioprinting tests with BIH/Charité; Positive animal trials in April 2025; €10M funding round in March 2026
Notable Customers
Charité – Universitätsmedizin Berlin; Berlin Institute of Health (BIH); Robert Koch Institute (RKI); Bayer; TissUse GmbH; Technische Universität Berlin (TU Berlin); Max Delbrück Center for Molecular Medicine (MDC); Leibniz Institute of Polymer Research Dresden; Orthopaedic University Hospital Heidelberg